Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

Our Pipeline

Leading the way for a new era in the treatment of rare genetic diseases.

Preclinical
Phase 1
Phase 2
Phase 3

QTORINTM rapamycin 3.9%

Pachyonychia Congenita

QTORINTM rapamycin 3.9%

Microcystic Lymphatic Malformations

QTORINTM rapamycin 3.9%

Gorlin Syndrome

PTX-014

Undisclosed Rare Disease
QTORINTM rapamycin 3.9%
Phase 3
Pachyonychia Congenita
QTORINTM rapamycin 3.9%
Phase 2
Microcystic Lymphatic Malformations
QTORINTM rapamycin 3.9%
Phase 2b
Gorlin Syndrome
PTX-014
Preclinical
Undisclosed Rare Disease

Our Programs

Pachyonychia Congenita (PC)

Pachyonychia Congenita (PC)

PC is a chronically debilitating rare genetic disease resulting in lifelong limited mobility and severe pain. There are no FDA approved therapies. Our phase 3 clinical study of QTORIN™ rapamycin 3.9% is expected to begin in late 2021. Palvella has been awarded both FDA Orphan Drug and Fast Track designation for this program.

Gorlin Syndrome

Gorlin Syndrome

Gorlin syndrome is a serious rare genetic disease where people may develop thousands of basal cell carcinomas, a form of cancerous skin tumors. There are no FDA approved therapies for Gorlin syndrome. Palvella is conducting a phase 2b clinical study of QTORIN™ rapamycin 3.9% for people with Gorlin syndrome.

 

Microcystic LM

Microcystic LM

Microcystic Lymphatic Malformations (Micro LM) is a rare genetic disease of the lymphatic system characterized by abnormal vessels or cysts that leads to chronic lymphorrhea, bleeding, pain, and a risk of severe life-threatening infections. There are no FDA approved therapies. Palvella is conducting a phase 2 clinical study for QTORIN™ rapamycin 3.9%, for people with this disease.

We’re uncovering more therapies every day. Stay updated.